Membrane for electrotransport transdermal drug delivery

• US 5,322,502 A
• Filed: 01/13/1993
• Issued: 06/21/1994
• Est. Priority Date: 10/03/1988
• Status: Expired due to Term

• Current Assignee: ALZA Corporation (Johnson & Johnson)
• Original Assignee: ALZA Corporation (Johnson & Johnson)
• Inventors: Gyory, J. Richard, Haak, Ronald P., Theeuwes, Felix
• Primary Examiner(s): Rosenbaum, C. Fred
• Assistant Examiner(s): Rafa, Michael
• Application Number:
  US08/003,761
• Time in Patent Office: 524 Days
• Field of Search: 128/798, 128/802, 128/803, 604/20, 604/49, 607/152
• US Class Current: 604/20
• CPC Class Codes: A61N 1/044 Shape of the electrode
• CPC Class Codes: A61N 1/0444 Membrane

Abstract

A membrane capable of inhibiting agent release from a delivery system when no electrical current is flowing and yet provide minimal impedance to electrically-assisted agent delivery, useful both for incorporating into electrotransport agent delivery systems and for use in measuring agent release rates in in vitro testing.

Claims

1. A device for administering a drug iontophoretically through a predetermined area of skin in a therapeutically effective regimen comprising:

(a) a first reservoir of said drug in a form susceptible to iontophoretic administration in communication with said area of skin;

(b) a skin permeability enhancer contained within said first reservoir;

(c) a first electrode in electrical communication with said first reservoir;

(d) a second reservoir containing a electrolyte in communication with the skin at a location separated from said area of skin;

(e) a second electrode in electrical communication with the second reservoir;

(f) means for creating an electric voltage difference between the first and second electrodes; and

(g) a rate controlling membrane interposed between said first reservoir and said area of skin, said membrane being substantially impermeable to the drug when the voltage difference is absent and permeable to the drug when the voltage difference is present.

2. The device of claim 1, wherein the second reservoir contains a drug in a form susceptible to iontophoretic administration.

3. The device of claim 1, wherein the second reservoir contains a skin permeability enhancer.

4. The device of claim 2, wherein a second rate controlling membrane is interposed between the second reservoir and the skin.

5. The device of claim 1, wherein at least one of the first and second electrodes is comprised of silver.

6. The device of claim 1, including means for controlling the magnitude of electrical current applied by the voltage difference.

7. The device of claim 6, wherein the means for controlling controls the magnitude of electrical current to a substantially constant level.

8. The device of claim 1, including means for controlling the duration over which the electrical voltage difference is applied.

9. The device of claim 1, including means for reversing the polarity of the voltage difference.

10. The device of claim 1, wherein at least one of the first and second reservoirs comprises a solution of said drug.

11. The device of claim 1, where at least one of the first and second reservoirs comprises a gel.

12. A method of administering a drug iontophoretically through a predetermined area of the skin of a patient comprising:

placing a first reservoir comprising the drug in communication with said area of skin, said first reservoir having a first electrode in electrical communication therewith;

placing a second reservoir containing an electrolyte in communication with the skin at a location separated from said area, said second reservoir having a second electrode in electrical communication therewith; and

creating a voltage difference between the first and second electrodes, wherein a skin permeability enhancer is applied to said area of skin to make the skin substantially permeable to the drug and a rate controlling membrane is interposed between the reservoir and the area of skin, the membrane being substantially impermeable to the dug in the absence of the voltage difference and permeable to the drug in the presence of the voltage difference.

13. The method of claim 12, wherein at least one of the first and second reservoirs comprises a solution of the drug.

14. The method of claim 12, wherein at least one of the first and second reservoirs comprises a gel.

15. The method of claim 12, including controlling the magnitude of electrical current applied by the voltage difference.

16. The method of claim 12, including controlling the duration of electrical current applied by the voltage difference.

17. The method of claim 12, including reversing the polarity of the voltage difference.